Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T88537
|
|||||
Target Name |
Mitochondrial protein unspecific (MP)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Alzheimer disease [ICD-11: 8A20] | |||||
2 | Type 2 diabetes mellitus [ICD-11: 5A11] | |||||
3 | Ataxic disorder [ICD-11: 8A03] | |||||
4 | Muscular dystrophy [ICD-11: 8C70] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | Mitoglitazone | Drug Info | Phase 2 | Type-2 diabetes | [2] | |
2 | EPICATECHIN | Drug Info | Phase 1/2 | Duchenne dystrophy | [1] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 2 Modulator drugs | + | ||||
1 | Mitoglitazone | Drug Info | [1], [3] | |||
2 | EPICATECHIN | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 2 | ClinicalTrials.gov (NCT01103414) Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients. U.S. National Institutes of Health. | |||||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.